CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 3 | 361,469 | $149K |
15 Form 4 filings on record, the earliest from Oct 8, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Open-market purchase | Common Stock | 100,000 | $0.44 | $44K | ||
| Open-market purchase | Common Stock | 251,136 | $0.40 | $100K | ||
| Open-market purchase | Common Stock | 10,333 | $0.43 | $4K | ||
| Grant or award | Common Stock | 100,000 | $0.64 | $64K | ||
| Grant or award | Stock Option (Right to Buy) | 22,000 | $0.00 | - | ||
| Grant or award | Common Stock | 70,000 | $0.00 | - | ||
| Grant or award | Stock Option (Right to Buy) | 95,000 | $0.00 | - | ||
| Grant or award | Stock Option (Right to Buy) | 22,000 | $0.00 | - | ||
| Grant or award | Common Stock | 105,600 | $0.00 | - | ||
| Grant or award | Stock Option (Right to Buy) | 136,400 | $0.00 | - | ||
| Grant or award | Common Stock | 71,500 | $0.00 | - | ||
| Grant or award | Stock Option (Right to Buy) | 90,000 | $0.00 | - | ||
| Grant or award | Common Stock | 89,100 | $0.00 | - | ||
| Grant or award | Stock Option (Right to Buy) | 111,100 | $0.00 | - | ||
| Edward Raymond Jones - Director | Grant or award | Stock Option (Right to Buy) | 22,000 | $0.00 | - | |
| Grant or award | Stock Option (Right to Buy) | 44,000 | $0.00 | - | ||
| Open-market purchase | Common Stock | 20,000 | $0.96 | $19K | ||
| Open-market purchase | Common Stock | 11,363 | $0.89 | $10K | ||
| Open-market purchase | Common Stock | 20,000 | $0.89 | $18K | ||
| Grant or award | Stock Option (Right to Buy) | 100,000 | - | - | ||
| Grant or award | Stock Option (Right to Buy) | 50,000 | - | - | ||
| Grant or award | Stock Option (Right to Buy) | 100,000 | - | - | ||
| Grant or award | Stock Option (Right to Buy) | 50,000 | - | - |
Cytosorbents Corp (CTSO) had 2 insider filings in the last 90 days, with the most recent on 2026-06-16. The full record for CTSO runs to 15 Form 4 filings, the earliest from 2024-10-08. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
3 insider purchases of CTSO were filed in the last 90 days, totaling $149K.
No insider sales of CTSO were filed in the last 90 days.
This page tracks CTSO Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add CTSO to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.